Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Iscience|November 2, 2020
Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn GlycoproteinDaniel Wright, Elizabeth R Allen, Madeleine H A Clark, et al.
Plos One|October 4, 2007
Haemoglobin C and S role in acquired immunity against Plasmodium falciparum malariaFederica Verra, Jacques Simpore, George M Warimwe, et al.
Vaccine|May 4, 2019
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact componentsSofiya Fedosyuk, Thomas Merritt, Marco Polo Peralta-Alvarez, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 1, 2022
Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populationsJames Nyagwange, Bernadette Kutima, Kennedy Mwai, et al.
Virology Journal|December 6, 2013
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in miceGeorge M Warimwe, Gema Lorenzo, Elena Lopez-Gil, et al.
BMC Infectious Diseases|February 19, 2021
Endemic chikungunya fever in Kenyan children: a prospective cohort studyDoris K Nyamwaya, Mark Otiende, Donwilliams O Omuoyo, et al.
The Journal of Clinical Investigation|August 2, 2012
Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunityJo-Anne Chan, Katherine B Howell, Linda Reiling, et al.
Scientific Reports|February 6, 2016
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley FeverGeorge M Warimwe, Joseph Gesharisha, B Veronica Carr, et al.
The Lancet. Infectious Diseases|April 15, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialDaniel Jenkin, Daniel Wright, Pedro M Folegatti, et al.
Cell Reports|December 28, 2018
A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever VirusElizabeth R Allen, Stefanie A Krumm, Jayna Raghwani, et al.
Pageof 7